Oppenheimer Sees 215% Upside in Viking Therapeutics as VK2735 Options Expand Beyond Near-Term Readouts
Wall Street stays bullish on VKTX as Oppenheimer sees expanded opportunities for VK2735 beyond near-term readouts and funding into 2028.
/ 19 items
#VKTX↓
Raymond James Highlights Viking’s New Amylin-Based Weight Loss Drug VK3019 Entering Clinic
Viking Therapeutics advances its obesity portfolio with the start of a Phase 1 trial for VK3019, a novel dual amylin and calcitonin receptor agonist. Analyst sees major potential.
Structure Therapeutics' Oral Obesity Pill Aleniglipron Hits Record 16.3% Weight Loss in Phase 2 Trial – Matches Injectables with No Plateau
Structure Therapeutics' oral pill aleniglipron achieved 15–16% body weight loss (up to 39 lbs) after 44 weeks in Phase 2, rivaling injectables with better tolerability and no plateau. Phase 3 is planned for 2026—a potential game changer for obesity treatment.
Viking Therapeutics Advances Oral Obesity Drug to Late-Stage Trials
Viking Therapeutics announces Phase 3 trials for its oral VK2735 obesity pill, showing up to 12.2% weight loss in early tests. Shares jump 9% as company eyes Q3 start.
Novo Nordisk Hunts for Deals After Losing Metsera to Pfizer
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
Novo Nordisk Launches Wegovy Weight-Loss Pill in the U.S.
Novo Nordisk's once-daily Wegovy pill launches in the U.S. at $149/month for self-paying customers, intensifying competition with Eli Lilly in the weight-loss drug market.